BioSpace News Archive

Biotech Bay

BioAge Labs to Present Data on Novel Brain-Penetrant NLRP3 Inhibitors for Treatment of Neurodegeneration and Brain Aging at Upcoming Conferences

BioAge Labs, Inc. announced that it will present updates on its NLRP3 inhibitor program at two upcoming conferences in the United States, Neurodegeneration Targets and the Inflammasome Therapeutics Summit, and at the BIO-Europe 2022 conference in Leipzig, Germany.

October 13, 2022
·
3 min read
Business

Biolase Names Dr. Russell Morrow as Chief Dental Officer

BIOLASE, Inc., a global leader in dental lasers, announced the appointment of Russell Morrow, D.D.S. as Chief Dental Officer, effective November 1, 2022.

October 13, 2022
·
5 min read
Genetown

Odyssey Therapeutics Announces Oversubscribed $168 Million Series B Financing

Odyssey Therapeutics, Inc., a biotechnology company pioneering next generation precision immunomodulators and oncology medicines, announced a $168 million Series B financing.

October 13, 2022
·
4 min read
Genetown

Walden Biosciences Announces Participation at October 2022 Investor Conferences

Walden Biosciences, Inc. announced that Blaine McKee, Ph.D., President and Chief Executive Officer of Walden Biosciences, will be participating in the following investor conferences during the month of October:

October 13, 2022
·
2 min read
Drug Development

Smart Immune and Greater Paris University Hospitals (AP-HP) begin groundbreaking Phase I/II trial with ProTcellTM, a thymus-empowered T-cell therapy platform, in adults with blood cancers

Smart Immune SAS announced today that SMART102, a human T-lymphoid progenitor cell injection derived from cord blood using Smart Immune’s ProTcell™ platform, has entered clinical testing in a trial sponsored and led by Great Paris University Hospitals (AP-HP).

October 13, 2022
·
5 min read
Samsung Biologics obtains three global ISO certifications

Samsung Biologics announced today it has successfully renewed its ISO 27001 certification (Information Security Management System) and obtained ISO 27017 certification (Information Security in cloud services) and ISO 37001 certification (Anti-bribery management systems).

October 13, 2022
·
2 min read
Lone Star Bio

Results from a Randomized Controlled Trial Show That TissueCypher® Barrett’s Esophagus Test Results Can Significantly Improve the Accuracy of Risk Assessments and Adherence to Guideline

Castle Biosciences, Inc. today announced new data from a randomized controlled trial (RCT) showing that use of TissueCypher® Barrett’s Esophagus Test results can significantly improve a physician’s accuracy in assessing the risk of progression to high-grade dysplasia (HGD) or esophageal adenocarcinoma (EAC) in patients diagnosed with Barrett’s esophagus (BE), as well as adherence to guideline-recommended patient management strategies.

October 13, 2022
·
6 min read
Can-Fite to Present its Phase IIb NASH Drug Candidate Namodenoson at Upcoming Conference

Can-Fite BioPharma Ltd. announced today the Company’s CEO Dr. Pnina Fishman will present its liver drug candidate, Namodenoson, at the H.C. Wainwright 6th Annual Conference.

October 13, 2022
·
6 min read
Zymeworks Completes Plan to Become Delaware Corporation

Zymeworks Inc. today announced the completion of its previously announced intention to complete a series of transactions (the “Redomicile Transactions”), resulting in the following: (i) Zymeworks Delaware Inc. (renamed as Zymeworks Inc.) (“New Zymeworks”) becoming the ultimate parent company incorporated in Delaware.

October 13, 2022
·
5 min read
Business

CCS Announces Innovative Partnership with Welldoc and ZeOmega Aimed at Helping People with Chronic Conditions Lead Healthier Lives while Reducing Healthcare Costs

CCS has announced a new technology partnership Welldoc and ZeOmega to expand its established LivingConnected® solution.

October 13, 2022
·
5 min read